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ABSTRACT 
 
Although, when injected, human Cardiac Primitive Cells (CPC) are not retained 
by host myocardium, they still improve cardiac function. Emerging evidence 
supports the hypothesis that exosomes may be responsible for beneficial effects 
induced by stem cells delivered in the infarcted myocardium. Exosomes are 
nano-sized vesicles naturally secreted by almost all cells and ubiquitously found 
in cell culture supernatants and biological fluids. Transporting and transferring 
peptides, lipids, and nucleic acids, exosomes have the potential to modulate 
signaling pathways, cell growth, migration, and proliferation of recipient cells. 
Accordingly, CPC may deliver chemoattractive, pro-survival and differentiating 
signals to resident cells through exosomes. To test our hypothesis, we isolated 
exosomes released in culture by CPC isolated from adult human myocardium 
(Exo-CPC) and analyzed the composition of their cargo and the effects elicited in 
vitro by their administration to resident population of CPC or fibroblasts. 
Specifically, we searched for the presence of specific factors known to regulate 
CPC migration, survival and differentiation. Additionally, we tested in vitro the 
potential of Exo-CPC of either regulating CPC proliferation and programmed 
cell death, and modulating interstitial fibrosis, extracellular-matrix (ECM) 
synthesis and deposition. Interestingly, on one hand, signals delivered by Exo-
CPC affected proliferation and survival of CPC and, on the other hand, regulated 
ECM protein production. Therefore, we might speculate that Exo-CPC have 
potential effect on both resident CPC and fibroblasts when injected in cardiac 
wall.  
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1. INTRODUCTION 
 
Within the last two decades the most challenging purpose of cardiovascular 
regenerative medicine has been the restoration of myocardial integrity and 
function by cell-based or stem cell-based therapies, small molecules and tissue 
engineering-based or material-based methods (1). 
The major approach in this field, to date, has been the replacement of lost or 
damaged tissues with new cells or to promote tissue regeneration by stem cell 
transplantation. Cell based therapy to treat the damaged heart, including injection 
of stem cells from various sources, have yielded mixed results in several species 
(2-4). Multiple experimental and several clinical studies have shown that 
different subsets of bone marrow-derived cells, isolated either from bone marrow 
(BM) or from peripheral blood, and other adult progenitor cells isolated from the 
cardiac tissue improved the recovery of heart function (5–11). Although the 
degree of improvement in cardiac function varies depending on the target 
population and cell type (8), there is mounting evidence that cell therapy is safe 
and does have a beneficial effect on left ventricle (LV) function (12) that 
translates into clinical benefit (10). One of the most important questions 
concerning cell therapies is to elucidate the mechanism by which stem/progenitor 
cells achieve functional improvement. A modest number of retained cells in the 
myocardium appeared to account for marked improvements in cardiac function 
as emerged from preclinical and clinical studies involving cell-based therapies 
(13). These observations have raised the possibility that grafted cells may 
amplify their effects by producing growth factors, cytokines, or other signaling 
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entities that improve the performance or survival of resident or recruited cells. 
Several studies have suggested that a paracrine mechanism contributes 
significantly to myocardial repair triggered by cell-based therapies (14-16). More 
recently, pluripotent cells derived from embryonic stem cells (ES) or induced 
pluripotent stem cells (iPSC), obtained by cutting-edge cellular reprogramming 
technologies, have been considered as an innovative source of modern cell 
therapies (17). In 2006, Takahashi and Yamanaka discovered that fully 
differentiated cells, such as skin cells from mouse, could be made pluripotent by 
artificially activating four specific genes. These cells, called iPSC, could self-
renew and differentiate like embryonic stem cells (18). The following year, iPSC 
were successfully reprogrammed from human skin cells too (19). iPSC provide a 
way to create genetically-matched pluripotent cells for patients, avoiding 
immune system incompatibility issues and ethical issues of embryonic stem cells.  
 
1.1 FROM BENCH TO CLINIC 
Although we are far from effective therapies, the positive outcomes of the 
clinical application of stem cell therapies has been remarkable, with thousands of 
trials currently registered in the National Institutes of Health clinical trials 
database (www.clinicaltrials.gov). Results from the early phase trials have 
demonstrated cell therapy as safe, feasible and potentially efficacious, in a wide 
range of diseases and medical fields, from cardiology (20), ischemic stroke (21) 
and peripheral ischemia (22), to cancer (23). Despite the enthusiastic results, for 
many of these therapies, therapeutic benefit cannot be attributed to stem cell 
9 
 
survival and differentiation, as they are not retained by organs (24-26). The 
beneficial effects of cell implants without cell survival and retention, along with 
well-researched trophic effects of the cell-conditioned culture medium suggest 
that secreted paracrine factors may be involved and could be responsible for the 
observed results (27,28). The paracrine hypothesis has been strengthened by the 
recent discovery that stem cells release not only soluble factors, like cytokines 
and chemokines, but also extracellular vesicles (EVs) eliciting similar biological 
activity to the stem cells themselves (28-31). 
 
1.2 EXOSOMES 
EVs are membrane surrounded structures released by cells in an evolutionarily 
conserved manner. Their diagnostic and therapeutic exploitation is now under 
intense investigation. 
Extracellular vesicles are heterogeneous and a consensus on terminology for their 
different subtypes is yet to emerge. The major populations include exosomes, 
microvesicles and apoptotic bodies. Exosomes size ranges between 40 and 100 
nm, and they are considered membrane vesicles of endocytic origin secreted by 
most cell types under normal and pathological conditions. Microvesicles are shed 
directly from the plasma membrane and can be larger than exosomes (50-1000 
nm) (32), (Fig 1 b), while apoptotic bodies originate at the cell membrane as cells 
undergo apoptosis (Fig 1 c). EVs can interact with target cells by two crucial 
mechanisms: transmembrane proteins on EVs can interact with receptors on the 
target cell membrane to initiate a signaling cascade (33, 34), or can directly fuse 
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with their target cells by endocytosis/transcytosis, with subsequent release of 
their content into the cytosol of the target cell. 
Among EVs, exosomes in particular, had gained immense research interest over 
the last few years due to their promising diagnostic and therapeutic potential (35) 
as cell-free approach (36). 
They were first described in a study to track the fate of recycling transferrin 
receptor during maturation of sheep reticulocytes (37). Exosomes have been 
found in a number of human body fluids, including blood plasma (38), urine 
(39), breast milk (40), amniotic fluid (41), (Fig 2). In 1940, Chargaff and others 
noted lipoproteins of a very high particle weight readily forming sediments in a 
strong centrifugal field but remaining in solution when subjected to weak 
centrifugal field (42). Despite the limited technology of the time, Chargaff & 
West (43) accurately predicted an important role of these particles in health and 
disease. Two decades later, Wolf and associates (44) isolated these particles from 
the subcellular fraction and resolved them using electron microscopy. Distinct 
small vesicles ranging from 20 to 50 nm were observed and were then termed 
platelet dust. The term exosomes was first coined by Johnstone and others to 
describe vesicles released from cultured maturing sheep reticulocytes (45, 46). 
These particles had enzymatic (e.g., acetylcholinesterase and transferrin) activity 
that was lost during reticulocyte-to-erythrocyte maturation. The first hypothesis 
was that these vesicles were a means to remove factors from the plasma 
membrane that were no longer needed by the mature erythrocyte (38). With the 
scientific progress, paracrine mechanisms became better understood and the field 
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of exosome biology spread out: particles once thought to be involved in waste 
management are now widely accepted as highly conserved elements in a pathway 
of short- and long-range communication. All the examined eukaryotic cell types, 
including hematopoietic cells, epithelial cells, neural cells, stem cells, adipocytes, 
and cancer cells secrete exosomes in culture (84). 
 
1.2.1 EXOSOMES BIOGENESIS 
The formation of exosomes starts from the cell surface, where proteins are 
internalized and delivered to early endosomes. In early endosomes, proteins can 
be recycled to the plasma membrane or delivered to late endosomes. By now, 
intraluminal endosomal vesicles are formed by budding of the endosomal 
limiting membrane into the lumen, forming multivesicular bodies (MVB). MVB 
can follow a different fate: they can fuse with lysosome for protein degradation, 
or merge with the plasma membrane, releasing the content into the extracellular 
space as exosomes (39, 47-48), (Fig 1 a). This mechanism presents an advantage 
to EV characterization, as exosomes can be further identified by markers of their 
biogenesis. Specifically, exosomes contain remnants of the ESCRT (endosomal 
sorting complexes required for transport) pathway, even if the markers associated 
with ESCRT are not entirely exclusive: some of the markers conserved in 
exosomes, such as tetraspanins (CD63, CD81, and CD9), are also present on the 
plasma membrane, in the cytosol, and in vesicles derived from membrane 
shedding (49). The wide presence of tetraspanins is likely due to the multiplicity 
of mechanisms in which these proteins are involved, including cell activation and 
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proliferation, cell adhesion and motility, and cell differentiation. The endosomal 
system controls the uptake and processing of various types of macromolecules 
from the extracellular environment and the plasma membrane into the cell. It 
consists of different interconnected vesicular organelles, basically the primary 
endocytic vesicles, the early endosomes, the recycling endosomes, the late 
endosomes and the lysosomes (50). The process of MVB formation is 
coordinated by the ESCRT. 
The ESCRT complexes are cytoplasmic proteins involved in membrane budding 
or bending events, such as multivesicular body biogenesis, the abscission step of 
cell division. This multiproteic structure, consisting of about thirty proteins, is 
assembled in four soluble complexes called ESCRT-0, ESCRT-I, ESCRT-II and 
ESCRT-III. The ESCRT-0 recognizes and sequesters ubiquitylated proteins in 
the endosomal membrane, whereas the ESCRT-I and -II appear to be responsible 
for membrane deformation into buds with sequestered cargo, and ESCRT-III 
components subsequently drive vesicle scission (51, 52), (Fig 3). The current 
knowledge of how MVBs are fated for either fuse with lysosomes to degrade 
their cargo or to fuse with the plasma membrane to release their intraluminal 
vesicles as exosomes into the extracellular environment is very preliminary. 
However, exosome production and release seem to depend on the activity of 
different Rab-GTPases and some of their effectors, which are known to regulate 
the vesicular transport between specific organelles (53). Rab proteins, reviewed 
in Stenmark 2009 (54), are essential regulators of intracellular vesicle transport 
between different compartments. Rabs can be involved in either vesicle budding, 
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mobility through interaction with the cytoskeleton, or tethering to the membrane 
of an acceptor compartment. The Rab family is composed of more than 60 
GTPases, each of which is preferentially associated with one intracellular 
compartment. 
RAB11 was the first Rab reported to be involved in exosome secretion. 
 
1.2.2 EXOSOMES STRUCTURE AND COMPONENTS 
Exosomes differ from each other in their composition, as they directly represent 
the proteome of the source cells. Analysis of urinary vesicles showed a link 
between exosomes containing aquaporin-2 and their origin from the urogenital 
tract (39). Several studies have shown that all mammalian exosomes share some 
common characteristics, for example the lipid bilayer structure, the size, the 
density and overall the composition in proteins. Some proteins are located on the 
surface, other in the lumen and are considered exosomal markers. Notably, these 
include cytoplasmic proteins such as tubulin, actin, actin-binding proteins, 
annexins and Rab proteins as well as molecules responsible for signal 
transduction, such as protein kinases and heterotrimeric G-proteins (55-57). Most 
exosomes also contain major histocompatibility complex class I (MHC I) 
molecules (58, 59) and heat-shock proteins such as Hsp70 and Hsp90 (60, 61). 
The protein family most commonly associated with exosomes is the tetraspanin 
including CD9, CD63, CD81 and CD82 (62-64). Consistent with their endosomal 
origin, there are typically no proteins of the nucleus, mitochondria, or 
endoplasmic reticulum detectable in exosomes (65).  
14 
 
Exosomes are also enriched in certain raft-associated lipids such as cholesterol 
(primarily B lymphocytes), ceramide (implicated in the differentiation of 
exosomes from lysosomes) other sphingolipids, and phospoglycerides with long 
and saturated fatty-acyl chains (66-68). Exosomes also show saccharide groups 
on their outer surface. This was investigated recently by Batista (69) who found 
that these were enriched in mannose, polylactosamine, α-2,6 sialic acid, and 
complex N-linked glycans. Exosomes have been reported to contain significant 
amounts of miRNA, other non-coding RNAs, as well as mRNA. Valadi et al. 
reported that, although the RNA appeared to be mostly degraded to less than 200 
nt fragments, some full-length molecules must also be present, since the 
extracted RNA could be used to generate identifiable full-length proteins using 
an in vitro translation system (70). Several papers indicate that the RNA “cargo” 
of exosomes is significantly different from the parental cell content, i.e. certain 
RNAs are present at significantly different levels compared to the total cell lysate 
from the originating cells (71-73).  
 
1.2.3 ROLES OF EXOSOMES 
Once exosomes are secreted outside the cells, they can follow one of these three 
pathways: 1) they can be captured by neighboring cells or by the same cells that 
have given rise to them; 2) they can be internalized by cells that are within a 
certain distance; or alternatively, 3) they can enter the systemic circulation and, 
then, be taken up by different tissues (47). Exosomes, once thought to be only 
responsible for the removal of unnecessary proteins from the cells, are now 
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considered the key factor in cell–cell communication (74). In addition, they 
participate in several different functions and in a large variety of pathways, such 
as immune response, cardiovascular protection and cancer. Exosomes, first 
simply considered a garbage cane, are now viewed as specifically secreted 
vesicles that enable intercellular communication and have become the focus of 
exponentially growing interest, both to study their functions and to understand 
ways to use them in the development of a non-invasive diagnostics and therapy. 
 
1.3 MYOCARDIUM SECRETES EXOSOMES 
Exosomes are demonstrated to be mediators of extracellular communicators; 
therefore, it is fitting to propose that they can be important communicators of 
ischemic signaling and myocardial repair. Reports have suggested that the 
myocardial tissue secretes exosomes, and exosomes and microvesicles could be 
an important mechanism involved in heterocellular communication in the adult 
heart (75, 76), especially exosomes emerging from telocytes in the border zone 
of myocardial infarction (MI) (76). Barile et al (75) provided ultrastructural 
evidence for the first time that exosomes and microvesicles are secreted by the 
progenitor cells in a normal adult mouse heart. They have also demonstrated a 
possible uptake of exosomes by cardiomyocytes in the adult mouse heart. 
Recently, Sahoo and Losordo provided ultrastructural evidence of exosome-like 
vesicles packed in MVBs of CPC from cardiospheres, characterized by a large 
nucleus and a thin cytoplasm, in a healthy mouse heart, as well as in the 
cytoplasm of cardiac myocytes (CMs) from the left ventricle of a healthy human 
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and from a patient with ischemic heart disease (77). Electronic microscopy 
observations showed that murine and human CPC are able to produce exosome-
like structures that are generated in MVBs (75, 77). These exosomes had a size 
of 30-90 nm and were enriched with proangiogenic miR-132, miR-146a and 
miR-210 that increased survival in cultured murine cardiomyocytes and induced 
tube formation in HUVEC cultures. Furthermore, treatment of rats with 
experimentally-induced IM by Exo-CPC resulted in the improvement of cardiac 
function, less profound cardiac apoptosis and enhanced intracardiac angiogenesis 
(78). 
 
1.4 EXOSOMES IN CARDIOVASCULAR DISEASE 
Intercellular communication mediated by extracellular vesicles is crucial for 
preserving vascular integrity and in the development of cardiovascular and other 
diseases. In cancer, exosomes have been described to possess the ability to pass 
on malignancy from cell to cell and shape the environment by stimulating blood 
vessel formation, while concomitantly inhibiting immune response to the tumor 
(79-81). 
In recent years, many published reports suggest that in addition to cancers and 
neurodegenerative disorders, major cardiovascular and metabolic pathologies 
like coronary artery disease, myocardial infarction, heart failure, and diabetes are 
highly influenced by the exosome-directed transfer of molecules. It has been 
demonstrated that exosomally delivered mRNA and miRNAs are translated and 
regulate gene expression of acceptor cells influencing their biology. They 
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contribute to the maintenance of cardiovascular and arterial homeostasis as well 
as their pathologies and play a functionally significant role in processes such as 
immune response, tumor progression, proliferation and apoptosis (70, 82-84). At 
present, several promising strategies for the application of exosomes in 
cardiovascular therapy are under development. Stem-cell-derived exosomes have 
a great therapeutic potential for cardiac repair in regenerative medicine. Further, 
exosomes could be used as nanoparticles for targeted delivery of various 
bioactive molecules, such as miRNAs. For example, endothelial-specific miR-
126 plays a key role in angiogenesis and vessel integrity and, therefore, could be 
used for vascular repair and regeneration (85). 
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2. HYPOTHESIS AND AIMS OF THE STUDY 
 
As exosomes are thought to play a crucial role in cell-cell communication and 
this communication may occur as a result of the transfer of important molecules 
and genetic material, we hypothesized they have the potential to modulate 
signaling pathways, cell growth, migration, survival and proliferation of recipient 
cells and even to modulate the extracellular compartment, by affecting fibroblast 
synthesis of ECM proteins. 
The overall aim of the study was to evaluate, in vitro, the effects on CPC and 
fibroblasts exerted by exosomes released by CPC isolated from adult human 
hearts. 
More specific aims were to: 
• isolate and characterize the composition of the cargo of exosomes delivered by 
CPC from both normal (Exo-CPC-N) and pathological (Exo-CPC-P) hearts in 
order to compare them with focus on the expression of growth factors and 
specific genes involved in cardiac development and differentiation. 
• determine whether exosomes contain mRNA involved in cardiac development 
and differentiation, and if so: 
• evaluate, in vitro, the effects elicited by the administration of Exo-CPC-N on 
CPC-P, in terms of cell proliferation, migration and survival; 
• evaluate, in vitro, the effects of Exo-CPC-N on CF-P in terms of extracellular 
matrix deposition.  
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3. MATERIALS AND METHODS 
 
3.1 CELL CULTURES 
Cardiac tissue samples were obtained from normal and pathological adult human 
hearts. Samples of atrial appendages from normal hearts (n=11, 6 males and 5 
females, mean age 35 ± 12 years) were collected from heart waste fragments of 
donors whose dead was not due to cardiovascular diseases, i.e. tissue trimmed off 
the heart while adjusting atrium size and form during organ transplantation. 
Pathological samples were taken from the corresponding region of explanted 
hearts of patients with end-stage heart failure due to ischemic cardiomyopathy 
and undergoing heart transplantation (n=20, 14 males and 6 females, mean age 
56 ± 5,5 years, mean ejection fraction 25 ± 1%). Cardiac tissue samples were 
dissected, minced, and enzymatically disaggregated by incubation in 0.25% 
trypsin and 0.1% (w/v) collagenase II (Sigma-Aldrich, St. Louis, MO, USA) for 
30 minutes at 37oC. The digestion was stopped by adding a double volume of 
Hank’s balanced salt solution (HBSS) supplemented with 10% foetal bovine 
serum (FBS). This preparation was further disaggregated by pipetting and tissue 
debris and cardiomyocytes were removed by sequential centrifugation at 100g 
for 2 minutes, passage through 20𝜇m sieve, and centrifugation at 400g for 5 
minutes. Cell population was seeded on culture dishes in Dulbecco's Modified 
Eagle Medium/Nutrient Mixture F-12 (DMEM/F-12, Sigma-Aldrich) 
supplemented with 10% FBS (Sigma-Aldrich), 5% horse serum (Sigma-Aldrich), 
10 ng/ml basic fibroblast growth factor (Peprotech, Rocky Hill, NJ, USA), 0.2 
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mM glutathione (Sigma-Aldrich), 5U/L erythropoietin, 50 µg/ml porcine 
gelatine, 10,000 U penicillin and 10 mg/ml streptomycin (Life Technologies, 
Paisley, UK). 
 
3.1.1 ISOLATION OF CARDIAC PRIMITIVE CELLS  
Once the adherent cells were more than 75% confluent, they were detached with 
0.25% trypsin-EDTA (Sigma-Aldrich) and cell suspension was used to isolate 
cardiac primitive cells by immunomagnetic cell sorting (Miltenyi Biotec, 
Bergisch Gladbach, Germany). In particular, cell suspension first depleted of 
fibroblasts, was incubated with anti-human-CD117 MicroBeads to select the 
positive fraction of CD117(+) CPC. Both CPC-N and CPC-P were plated at a 
2x104/cm2 density and cultured with DMEM-Ham F12 medium (Sigma-Aldrich). 
To check effectiveness of sorting, cells were fixed in 4% paraformaldehyde for 
20 minutes at room temperature, blocked with 10% donkey serum and stained 
with primary antibody against human stem cell marker CD117 (mouse 
monoclonal, Merck Millipore, Billerica, Massachusetts, USA) Cells were then 
incubated with secondary antibodies conjugated with rhodamine (Jackson 
ImmunoResearch Europe, Newmarket, UK). Nuclei were counterstained with 
DAPI (Merck Millipore) and stained area of culture dish was mounted in 
Vectashield (Vector Labs, Burlingame, CA, USA). Microscopic analysis was 
performed with a Leica DMLB microscope equipped with epifluorescence 
EL6000 system (Leica Microsystems, Wetzlar, Germany) and connected to a 
digital camera DFC345FX (Leica Microsystems). 
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3.1.2 ISOLATION OF CARDIAC FIBROBLASTS 
CF-P were isolated by outgrowth. Briefly, small fragments of specimens were 
placed in culture plates under cover glass and incubated with Dulbecco's 
Modified Eagle Medium (DMEM, Sigma-Aldrich) supplemented with 10% FBS 
(Sigma-Aldrich) and 0.5% penicillin and streptomycin (Life Technologies) in a 
humidified incubator at 37°C and 5% CO2 in air. The medium was exchanged 
every 2-3 days to remove cell debris and maintain a physiological pH. 
 
3.2 ISOLATION OF EXOSOMES FROM CELL CULTURES 
Once CPC-N and CPC-P were 80-90% confluent, complete medium was 
replaced with a serum-free medium, which was collected after 48h and processed 
in order to isolate exosomes by ExoQuick-TC Exosome Precipitation Solution kit 
(System Biosciences, Mountain View, CA, USA). After a centrifugation at 3000 
rpm for 15 minutes at 4°C to eliminate cells and cellular debris, the medium was 
incubated overnight at 4°C, with a polymeric resin, specific for exosomes 
isolation, according to the manufacturer’s protocol. The pellet, containing 
exosomes obtained from the two populations of cells (Exo-CPC-N and Exo-
CPC-P), was used to perform specific assays to analyze the content of their 
cargo.  
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3.3. ANALYSIS OF mRNA BY REAL-TIME PCR  
3.3.1 PURIFICATION AND ISOLATION OF RNA FROM EXOSOMES 
Pellet was resuspended in 700 μl of Trizol (Invitrogen, Thermo Fisher Scientific, 
Carlsbad, CA, USA); the solution was vortexed and incubated at room 
temperature for 5 minutes for a complete dissolution of nucleoproteic complexes. 
A volume of 90 μl of chloroform was added to the resulting lysate and after a 
vigorous agitation and a centrifugation at 1200 rpm for 15 minutes at 4°C, the 
aqueous phase, holding the total RNA, was collected. The further steps of the 
extraction were performed using RNeasy Micro kit (Qiagen, Hilden, Germany) 
with columns equipped with high affinity silicium membranes, according to the 
manufacturer’s protocol. The RNA obtained was resuspended in 14 µl of RNase-
free water and quantified by spectrophotometric analysis with Nanodrop2000 
(Thermo Scientific). 
 
3.3.2 cDNA SYNTHESIS 
RNA extracted as described above, was then retrotranscribed into cDNA with 
QuantiTect Reverse Transcription kit (Qiagen). According to the manufacturer’s 
protocol, 50 ng of each RNA were incubated for 2 minutes at 42°C with the 
reagent gDNA Wipeout Buffer, to eliminate remaining traces of genomic DNA in 
samples. To each sample was then added a reverse transcriptase enzyme 
(Quantiscript Reverse Transcriptase), deoxynucleotides and a mixture of primers 
containing both oligo (dT) and random hexamers; samples were further 
incubated for 20 minutes at 42°C and finally, for 3 minutes at 95 °C to deactivate 
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the enzyme. 
 
3.3.3. REAL-TIME PCR 
In order to assess the presence and the quantity of specific transcripts, a Real-
Time PCR was performed using PrecisionPLUSTM MasterMix kit (Primerdesign, 
Southampton, UK) according to manufacturer’s protocol. 
The detection was performed by measuring the binding of the fluorescent dye 
SYBR Green I to double-stranded DNA. DNA amplification was carried out 
using Mastercycler ep realplex4S (Eppendorf, Hamburg, Germany); the thermal 
cycling conditions included an initial enzyme activation at 95°C for 2 minutes 
and 40 cycles consisting of a denaturation step at 95°C for 15 seconds and an 
annealing step at 60°C for 60 seconds. Melt curve analysis was used to assess 
amplification of non-specific products and uniformity of product and primer 
dimers formation. Comparative quantification of target genes expression in the 
samples was based on cycle threshold (Ct) normalized to the housekeeping gene 
(GAPDH), using the 2-∆∆Ct method (Livak and Schmittgen, 2001). All the primers 
used in this study, listed in table 1, were designed with Primer3 software 
(http://frodo.wi.mit.edu) starting from the CDS (coding sequence) of mature 
mRNA available on GeneBank. 
The PCR products were size-fractionated by electrophoresis in 2% agarose gel. 
The DNA bands were visualized and photographed under UV light exposure with 
FireReader XS D-55 imaging system equipped with 1D software (UVItec 
Limited, Cambridge, UK). To assess the length of amplicons, each product was 
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compared with a known molecular weight marker (BenchTop pGEM DNA 
marker, Promega, Madison, WI, USA). 
 
3.4. EXOSOME LYSATES AND QUANTIFICATION OF PROTEIN 
CONTENT 
Protein extracts were prepared from both Exo-CPC-P and Exo-CPC-N. Pellet 
obtained as described previously, was resuspended in 200 µl of RIPA buffer 
solution (Tris-HCl pH 7.6 25 mM, NaCl 150 mM NP-40 1%, sodium 
deoxyicholate 1%, SDS 0.1%) containing prothease inhibitors (1 mM DTT, 2 
mM PMSF, 2 μg/ml aprotinin and 10 μg/ml leupeptin), to promote the disruption 
of exosomes, vortexed for 15 seconds and incubated at room temperature for 5 
minutes. Protein concentration was determined by Bio-Rad Protein Assay (Bio-
Rad Laboratories, Hercules, CA, USA) using as a standard albumin from bovine 
serum (Sigma-Aldrich). 
 
3.4.1. GROWTH FACTORS ARRAY 
In order to determine the content of Growth Factors in exosome cargo, protein 
array was performed on both Exo-CPC-P and Exo-CPC-N, using Human Growth 
Factor Antibody Array C1 kit (RayBio®, Norcross, GA, USA), according to the 
manufacturer’s protocol.  
The array membranes bounding primary antibodies were blocked and incubated 
with each sample (100 µg of protein).  
After washing, the membranes were incubated with a cocktail of biotin-
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conjugated antibodies, followed by an incubation with HRP-conjugated 
streptavidin in blocking buffer. Signals were detected by chemiluminescence and 
autoradiography. 
 
3.5 EXOSOME ADMINISTRATION IN VITRO 
3.5.1 PREPARATION AND ADMINISTRATION OF EXOSOMES 
CONDITIONED MEDIUM TO CPC-P 
Based on results obtained with real-time PCR and growth factor array Exo-CPC-
N from cardiac primitive cells isolated from normal hearts were used to prepare a 
conditioned medium, to test, in vitro, effects elicited by exosomes on both CPC-P 
and CF-P.  
Exo-CPC-N were resuspended in specific medium at a concentration of 0,5 
mg/ml and added to CPC-P and CF-P in culture. After treatment, morphology of 
cells was evaluated by phase contrast microscope observation with Nikon Eclipse 
Ti-E DS-Qi2 Microscope (Nikon Instruments Europe, Holland). 
 
3.5.2 EVALUATION OF PROLIFERATION AND APOPTOSIS OF 
CARDIAC PRIMITIVE CELLS 
To evaluate proliferation and apoptosis, CPC-P treated with Exo-CPC-N and 
CPC-P not treated with Exo-CPC-N (control group) were stained with Cell-
Clock Cell Cycle Assay (Biocolor, UK) and Cell-ApoPercentage Apoptosis 
Assay (Biocolor), respectively, according to the manufacturer’s protocol. In 
particular, the first assay is a live-cell detection system employed to monitor the 
four major phases of the mammalian cell cycle during in vitro culture. Cells were 
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incubated at 37°C for 1 hour with a redox dye, taken up by live cells. Following 
dye uptake and incubation, a distinct color change occurs within cells, with 
particular color changes being associated with cells in the G1, S, G2 and M 
phases of the cycle.  
Cell-ApoPercentage Apoptosis Assay, instead, is a detection and measurement 
system to monitor the occurrence of apoptosis in mammalian, anchorage-
dependent cells during in vitro culture. CPC-P with or without Exo-CPC-N were 
first incubated with 3% hydrogen peroxide in the complete medium for 12 hours 
and stained with the ApoPercentage dye that is selectively imported by cells that 
are undergoing apoptosis. 
Microscopic analysis was performed with a Leica DM2000 LED microscope 
(Leica Microsystems) equipped with a digital camera Leica ICC50 HD (Leica 
Microsystems). Data were expressed as mean percentage of cycling cells over 
total cells + SEM for Cell-Clock Cell Cycle Assay, and as mean percentage of 
stained cells over total cells for Cell-ApoPercentage Apoptosis Assay. 
 
3.5.3 EVALUATION OF MIGRATION OF CARDIAC PRIMITIVE 
CELLS 
To evaluate the speed of migration of CPC-P in the absence (control group) or 
presence of Exo-CPC-N, scratch wound assay was performed. Briefly, cells were 
grown to confluence and a thin scratch was produced in straight line on culture 
plates with a 10 µl pipette tip, leaving a cell-free zone. Plates were placed under 
Nikon Eclipse Ti-E DS-Qi2 Microscope (Nikon Instruments Europe) equipped 
with stage incubator (Okolab, Pozzuoli, Italy) and the migration was documented 
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acquiring one picture every 10 minutes for 8 hours. Data were analysed by NIS 
software (Nikon) and expressed as mean speed of migration + SEM. 
 
3.5.4 EVALUATION OF MATRIX DEPOSITION BY FIBROBLASTS 
In order to evaluate effects of Exo-CPC-N on the deposition of ECM, CF-P 
treated with Exo-CPC-N and CF-P not treated with Exo-CPC-N (control group) 
were fixed in 4% paraformaldehyde for 20 minutes at room temperature. After 
blocking with 10% donkey serum, plates were first incubated with primary 
antibody against human fibronectin (rabbit polyclonal, Sigma-Aldrich), human 
collagen I (mouse monoclonal, Sigma-Aldrich), collagen III (mouse monoclonal, 
Sigma-Aldrich), collagen IV (rabbit monoclonal, Sigma-Aldrich) human laminin 
(mouse monoclonal, Sigma-Aldrich), and tenascin (mouse monoclonal, Sigma-
Aldrich), for 1 hour at 37°C and then were incubated for 1 hour at 37°C with 
secondary antibodies conjugated with fluorescein or rhodamine (Jackson 
ImmunoResearch Europe). Nuclei were counterstained with 4’-6-diamidino-2-
phenylindole (DAPI) (Merck Millipore) and stained area of culture dish was 
mounted in Vectashield (Vector Labs). Microscopic analysis was performed with 
Nikon Eclipse Ti-E Microscope DS-Qi2 (Nikon Instruments Europe) by three 
independent observers. Synthesis and deposition of ECM proteins was compared 
in treated and untreated using an arbitrary scale ranging from negative (-) in case 
of immunonegativity, to triple positive (+++), in case of strong 
immunopositivity. 
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3.6 STATISTICAL ANALYSIS 
All numerical data are presented as mean ± SEM. Statistical differences between 
groups were evaluated with Student’s two-tailed unpaired t-test. A value of 
p<0.05 was considered statistically significant. 
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4. RESULTS 
 
4.1 CELL CULTURES 
Observation by phase contrast microscope provided images of primary cell 
cultures (Fig 4) obtained from normal (A) and pathological (B) adult human 
hearts. Phase contrast microscope image of CF-P are shown in Fig 5. 
 
4.1.1 CHARACTERIZATION OF CPC POPULATION 
Immunofluorescence for CD117 confirmed the purity of cell population obtained 
by immunomagnetic cell sorting from primary cardiac cell culture (as described 
in Materials and Methods section 3.1.1). Purity of sorted cells reached 98% (Fig 
6). Phase contrast microscope images show sorted populations of both CPC-N 
(Fig 7 A) and CPC-P (Fig 7 B). 
 
4.2 REAL-TIME PCR 
The pellet obtained after centrifugation of medium collected from CPC-N and 
CPC-P in culture, was significant and sufficient to extract RNA. 
qPCR analysis of Exo-CPC cargo revealed that Exo-CPC-N and Exo-CPC-P 
carry specific transcripts for proteins involved in cardiac and mesenchymal 
differentiation. 
Notably, exosomes delivered by both CPC-N and CPC-P transport specific 
transcripts for cardiac cell progenitors or precursors of cardiomyocyte, as Mef2C, 
Nkx2.5 and Alpha Sarcomeric Actin (α-SARC), and smooth muscle cells 
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(SMCs), as GATA6 and Smooth Muscle Actin (SMA). Further, they also carry 
transcripts for mesenchymal cells, as TM4SF1, SOX9, CD90 and CD106 (Fig 8). 
No transcripts were found for proteins that prompt endothelial lineage 
differentiation, like FVIII and Ets-1. Comparing expression levels obtained with 
the 2-∆∆Ct method for mRNAs from Exo-CPC-N and EXO-CPC-P, statistically 
significant differences only emerged for Mef2C (fold change 0.32 + 0.04) and 
Nkx2.5 (fold change 0.25 + 0.00), mainly carried by Exo-CPC-N, and for SMA 
(fold change 8.63 + 0.8) and TM4SF1 (fold change 3.08 + 0.14) mainly carried 
by Exo-CPC-P (Fig 9). 
 
4.3 GROWTH FACTORS ARRAY 
Protein array performed to analyze growth factor cargo of Exo-CPC, revealed 
differences in the content of Exo-CPC-N and Exo-CPC-P. The comparison of the 
two membranes clearly showed that Exo-CPC-N carried factors mostly involved 
in biological processes like cell proliferation and differentiation, as EGF 
(Epidermal Growth Factor), FGF-6 and FGF-7 (Fibroblasts Growth Factors-6 
and 7). Further, they show a considerably higher amount of IGF-1 (Insulin Like 
Growth Factor) which is a potent modulator of stem cell replication, commitment 
to the myocyte lineage and differentiation, and SCF (Stem Cell Factor) 
responsible for preserving stem cells characteristics and guiding them to niches. 
On the contrary, they did not carry factors involved in tumorigenesis and 
angiogenesis processes, as TGF (Transforming Growth Factor), HGF 
(Hepatocyte Growth Factor) nor VEGF (Vascular Endothelial Growth Factor) at 
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all, clearly present in Exo-CPC-P. Additionally, a higher expression of receptors 
VEGFR2, VEGFR3 and SCFR in Exo-CPC-P emerged. The assay did not reveal, 
in Exo-CPC-N, the presence of receptors like SCFR, EGFR, PDGFRα and 
PDGFRβ, essential for mediation of signals and cell/tissue response (Fig 10). 
 
4.4 PROLIFERATION AND APOPTOSIS OF CPC 
After treatment with specific dye, microscopic analysis of CPC-P in culture with 
or without Exo-CPC-N revealed that although morphology did not differ 
significantly (Fig 11; A, B; Fig 12; A, B), the presence of Exo-CPC-N clearly 
affects both proliferation and apoptosis. Notably, CPC-P treated with Exo-CPC-
N showed higher proliferation rate compared to control group, as indicated by the 
ratio of cells in S to M phases (Fig 11; C, D). In the presence of Exo-CPC-N the 
proportion of proliferating cells in M phase reached a percentage of 20.52 + 
4.43%, while the control group showed a lower amount of proliferating cells in 
the same phase, equal to 1.068 + 0.79%. The percentage of cells in G2-S phase 
was 14.19 + 0.63% in CPC-P treated with Exo-CPC-N, against a 27.48 + 2.13% 
observed in CPC-P untreated. No statistically significant differences were 
observed for cells in G1 phase, that showed a percentage of 65.28 + 5.04 and 
71.45 + 2.42% for CPC-P treated with Exo-CPC-N and untreated, respectively 
(Fig 11 E). 
From microscopic analysis also appeared that the presence of Exo-CPC-N 
prevented CPC-P apoptosis induced by oxidative stress, as demonstrated by the 
lower amount of nuclei stained with the dye, selective for apoptotic cells (Fig 12; 
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C, D). In fact, oxidative stress, in vitro, induced apoptosis in only 2.25 + 0.31% 
in case of CPC-P treated with Exo-CPC-N, while untreated CPC-P resulted more 
susceptible to apoptosis, showing a higher percentage of apoptotic nuclei, equal 
to 26.74 + 8.08% (Fig 12 E). 
 
4.5 MIGRATION OF CPC 
The scratch wound assay performed, is a simple, reproducible assay commonly 
used to measure basic cell migration parameters such as speed, persistence and 
polarity. Cells at the wound edge polarize and migrate into the wound space. Cell 
migration was monitored in real time by time-lapse imaging which can also yield 
valuable cell morphology and localization. Scratched area of cell monolayer was 
recorded every 10 minutes for 8 hours (Fig 13). Results obtained indicated that 
migration is not affected by administration of Exo-CPC-N, as the speed of 
migration appeared almost the same in CPC-P treated with exosomes (11.28 + 
1.34) compared to control group (11.43 + 1.31) (Fig 13 E). After the scratch, cell 
migration was observed both in CPC-P untreated and treated with Exo-CPC-N, 
but full wound healing only occurs after 8 hours for both cell populations (Fig 
13; C, D). 
 
4.6 MATRIX DEPOSITION BY FIBROBLASTS 
Immunostaining performed on CF-P showed effects exerted by Exo-CPC-N on 
different extracellular matrix proteins, their deposition and synthesis (Fig 14). In 
general, when cultured in Exo-CPC-N conditioned medium, CF-P exhibited less 
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elongated morphology. From microscopic observation CF-P treated with Exo-
CPC-N showed a stronger immunopositivity for collagen IV (Fig 14 F), while no 
significantly differences were found for collagen I and III, all proteins providing 
tensile strength and structural integrity, but also playing a role in cell adhesion 
and migration. Fibronectin, that influences cell growth and response to injury, 
like wound repair, shows a dramatic higher expression and well-arranged pattern 
in treated CF-P compared to control group, as indicated by the more intense 
emission of fluorescence (Fig 14; D, H). On the contrary, synthesis of laminin, 
important for activating specific signaling networks governing adhesion, 
migration and differentiation, decreased in the presence of Exo-CPC-N (Fig 14; 
G). Finally, tenascin, associated with cell migration, especially fibroblast 
migration and epithelial-mesenchymal/mesenchymal-epithelial transition did not 
show consistent differences in the presence or absence of Exo-CPC-N in CF-P in 
culture. Differences observed for synthesis and deposition of collagen IV, 
laminin and fibronectin are summarized in Tab 2. 
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5. DISCUSSION AND CONCLUSION 
 
Stem cells or progenitor cells are presently our best therapeutic candidate to treat 
intractable degenerative or genetic diseases. In fact, many of these stem or 
progenitor cells are being tested in clinical trials to treat many different diseases 
such as acute myocardial infarction. The hypothesis that stem cells could exert 
therapeutic activity through their secretions is highly plausible as stem cell 
secretions are known to include many biologically potent molecules such as 
growth factors, cytokines, chemokines, and bioactive lipids that could elicit 
wide-ranging physiological effects (86). Growing evidence suggest that adult 
stem cells may exert dramatic effects in the repair of various tissues through 
secreted factors including exosomes and EVs (87). Indeed, up to 80% of the 
therapeutic activities of adult stem cells in infarcted hearts have been shown to 
occur through paracrine mediated effects (88), giving rise to the novel notion of 
stem cell therapy without cells (87). Exosomes are secreted by cardiac and 
vascular cells and stem cells in culture (89, 90-92). Moreover, exosomes have 
been shown to mediate communication between endothelial cells (ECs) and 
SMCs (93), ECs and pericytes (94), CMs and ECs (95) and fibroblasts and 
cardiac myocytes CMs (96). Recently, Sahoo and Losordo (77) provided 
ultrastructural evidence of exosome-like vesicles packed in MVBs of a CPC in a 
healthy mouse heart, as well as in the cytoplasm of CMs from the left ventricle of 
a healthy human and from a patient with ischemic heart disease. Very few 
studies, including the present study, have investigated the therapeutic potential of 
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human Exo-CPC and characterized the content of their cargo. In particular, we 
determined the presence of specific growth factors in Exo-CPC-N and Exo-CPC-
P. Protein array for growth factors revealed remarkable differences between the 
content of Exo-CPC-N and Exo-CPC-P suggesting that exosomes secreted by 
CPC-N could be the best candidate to treat cardiac diseases. As a matter of fact, 
we found that Exo-CPC-N carry growth factors involved in biological processes 
like cell proliferation, development, differentiation and migration (EGF, FGF-6, 
FGF-7, IGF-1) (97), and the SCF, exerting a crucial role in maintenance of stem 
cells compartment. All these factors could potentially boost cardiac repair mainly 
through endogenous stem cell homing and activation. Exo-CPC-P, instead, 
transport considerably higher amount of growth factors mainly involved in 
tumorigenesis and angiogenesis (TGF, HGF, VEGF), strengthening the 
hypothesis that cardiac disease affect CPC compartment too, and that Exo-CPC-
N are preferable candidates for treating cardiovascular diseases. However, CPC-
P transport higher amount of receptors like VEGFR2, VEGFR3 and SCFR, 
stimulating angiogenesis, essential to prevent heart failure through the control of 
cardiomyocyte hypertrophy and contractility and ensuring promptness to respond 
to SCF stimulation. In addition to growth factors, exosomes are lipid vesicles, 
which represent ideal vehicles to deliver genetic materials, such as mRNA, from 
one cell to another, and fulfill their function. In recent years, many published 
reports suggest that in addition to cancers and neurodegenerative disorders, major 
cardiovascular and metabolic pathologies like coronary artery disease, 
myocardial infarction and heart failure are highly influenced by the exosome-
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directed transfer of molecules (98-100). It has been demonstrated that 
exosomally delivered mRNAs and miRNAs are translated and regulate gene 
expression of acceptor cells influencing their biology (101). Our findings by 
Real-time PCR analysis of Exo-CPC cargo revealed the presence of transcripts 
specific for cardiac or mesenchymal differentiation in Exo-CPC-N as well as in 
Exo-CPC-P. A primary obstacle to functional recovery of the infarcted or failing 
human heart is the limited proliferative capacity of cardiomyocytes and their 
insufficient mechanism for regeneration. The loss of cardiomyocytes after injury, 
in fact, cannot be compensated and a strategy to replace them could be inducing 
resident CPC to differentiate to new, healthy cardiomyocytes. Hence, Exo-CPC-
N, seem to be suitable candidates for a therapeutic approach, as they show a best 
potential of delivering signals to prompt differentiation to cardiomyocyte, 
expressing higher levels of Nkx2.5 and Mef2c, while in Exo-CPC-P we found 
signals inducing mostly smooth muscle or mesenchymal cell differentiation, as 
they expressed high levels of SMA and TM4SF1. Additionally, the delivery of 
CPC-N secreted factors to CPC-P might lead CPC-P ahead of the differentiation 
block which prevents progenitors to proceed towards precursor state, already 
documented (102). The diversity of this EV content provides a rationale for the 
many reported stem cell-based therapeutic outcomes. With increasing evidence 
that EVs are major mediators of intercellular communication in many cell types 
(103, 104), it is likely that EVs also perform similar functions for stem cells. As 
such, EVs are likely to support the hypothesis that stem cells exert therapeutic 
activity through their secretions by communicating therapeutic signals from stem 
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cells to recipient cells to initiate repair and regeneration. EVs from CPC have 
also been reported to be efficacious in cardiovascular disease; in particular, they 
inhibited cardiomyocyte apoptosis and improved cardiac function after MI in 
animal models, ameliorated the deleterious consequences of myocardial 
ischemia, and enhanced cardiogenesis (105-108). Further, exosomes enhanced 
endothelial migration and were also shown to reduce myoblast apoptosis in vitro 
and decrease myocyte cell death in an animal MI model (106). Here, we tested, 
in vitro, potential effects exerted by Exo-CPC-N on capacity for migration, 
proliferation and susceptibility to apoptosis of CPC-P. On the basis of results 
obtained from analysis of Exo-CPC cargo, we considered plausible exclusively 
administrating Exo-CPC-N to CPC-P and CF-P. A similar speed of migration 
was observed for CPC-P either in the presence or absence of Exo-CPC-N, 
probably due to growth factors enhancing migration, found both in Exo-CPC-N 
(IGF1 and FGF6) and Exo-CPC-P (HGF). We also reported that, even if 
morphology did not differ significantly, probably due to presence of specific 
growth factors, CPC-P treated with Exo-CPC-N conditioned medium had an 
increased proliferation rate, as demonstrated by the ratio of cells in active phases 
of cell cycle. At the same time, it was apparent that Exo-CPC-N could represent 
cardioprotective factors for CPC-P, preventing apoptosis induced by oxidative 
stress. 
It is well-researched that the fate of the cell is determined by coordinated and 
dynamic interactions among a number of factors, acting in a defined 
microenviroment. In particular, stem cells are highly sensitive to extracellular 
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signals that play a critical role in maintenance of stem cells characteristics, 
differentiation, and interplay with somatic cells (109). Cellular cross talk plays a 
central role both in cardiac homeostasis and in adaptive responses of the heart to 
stress. Chronic adaptive responses to stress, referred to as cardiac remodeling, 
include interstitial fibrosis, CMs hypertrophy, and changes in contractility and 
blood vessel density (110). Post MI, the proliferation of fibroblasts lead to the 
formation of non-contractile scar tissue (111), which, when combined with the 
extensive cardiomyocyte death (77), leads to long-term systolic dysfunction. In 
the damaged heart, fibroblasts are stimulated by cytokines such as TGF-β, which 
leads to exacerbation of extracellular matrix production (112), and enhanced 
fibrosis (113). CPC have been shown to exert potentially anti-fibrotic effects by 
transferring exosomes to fibroblasts and by promoting cardiac myocyte survival 
in vitro (94).  In this study, we investigated if Exo-CPC-N produced any 
changing in the synthesis and deposition of ECM by CF-P, and if any difference 
occurred analyzing composition of ECM in terms of proteins and comparing 
them to the control group. ECM account for approximately 24% of myocardial 
volume and network rearrangement and enlargement is an essential component 
of cardiac remodeling at various pathological stages (114). The ECM elasticity 
determines stem cell lineage specification, expansion and differentiation (115) 
and (116), in the heart, ECM exhibits all the mechanical properties and provides 
a framework required for differentiation of cardiac stem cells (117). In any 
necrotic tissue, fibronectin and collagen deposition and disarrangement is 
responsible for scar formation, which preserves wall integrity and thickness. 
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These proteins present unique expression pattern, with high levels during 
organogenesis, virtual absence in normal adult tissue, and re expression in 
response to injury and tissue regeneration. In the heart, osteopontin, osteonectin, 
thrombospondin, tenascin, and CNN family are the matricellular proteins 
identified so far (118), but laminin-1 also fulfills the requirements (119). Given 
these properties, extracellular matrix, and matricellular proteins in particular, can 
drive cardiac tissue regeneration, described in adult human heart in infarction or 
pressure overload (120). From the observation of CF-P in culture with Exo-CPC-
N conditioned medium emerged differences in the deposition of collagen IV and 
fibronectin, while synthesis of collagen I and collagen III remained almost 
constant when compared to the control group. Interestingly, synthesis of laminin 
seemed to slightly decrease in CF-P treated with Exo-CPC-N. Moreover, Exo-
CPC-N seem to revert fibronectin disarrangement in vitro, conferring to 
mentioned ECM protein deposit an ordered and organized pattern. These 
changings could validate our hypothesis that Exo-CPC-N could positively affect 
the extracellular compartment during the response to injury.  
There is now ample evidence of the effective recapitulation of the therapeutic 
efficacy of stem cells by their secreted EVs. This renders stem cell-derived 
extracellular vesicles a compelling alternative off-the-shelf, cell-free therapeutic 
modality that could be effective, safer, and cheaper. However, realizing this 
promising therapeutic modality of stem cell EVs would require extensive testing 
to validate their safety and efficacy (121). 
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The use of stem cell-derived EVs instead of stem cells engraftment might open 
new perspectives for cardiac regenerative therapies. This would first resolve 
safety concerns related to uncontrolled dissemination of transplanted cells or 
aberrant stem cell differentiation. In addition, immunosuppressive effects 
reported for certain EVs could favor efficient cardiac tissue regeneration (122). 
Moreover, since exosomes could be easily stored and keep their biological 
properties over an extended storage period, they can overcome many of the 
limitations linked to the use of viable cells in regenerative medicine. However, 
further investigations would be needed to optimize their characterization, quality, 
and purification in order to accurately control their production in the perspective 
of clinical uses (123). 
Cell-based therapy for cardiovascular disorders experiences only limited success 
due to cells retention and engraftment issues as well as potential 
immunogenicity. Exosome-based treatment options, however, provide cell-free 
therapeutic candidates that offer to provide comparable benefits. One of the most 
active areas of translational research is to identify the most effective cell type and 
enviroment for generation of most effective cardio-protective and cardio-
regenerative exosomes (89, 124, 125).  
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6. ICONOGRAPHY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
A. Ibrahim and E. Marban, Annual Review of Physical Chemistry; 2016 
Fig. 1 
Formation of two different multivesicular bodies (MVBs) through invagination 
of the plasma membrane (a). Steps 1–4 (red): Invagination of the plasma 
membrane to form a secretory endosome (1), followed by budding of payload 
into the endosomal membrane to form multivesicular endosomes (2). Maturation 
of the late endosome through acidification (3) triggers fusion with the plasma 
membrane and release of exosomes (4). Representation of microvesicles (b) 
andapoptotic bodies (c). 
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Fig. 2 
Exosomes are nanosized particles with a diameter range of 30–100 nm, enriched in 
various types of lipids, and secreted by all cell types. Markers ubiquitous in most 
exosomes include tetraspanins (CD9, CD63, and CD81); heat shock proteins; 
adhesion molecules; and markers of the ESCRT (endosomal sorting complexes 
required for transport) pathway, including LAMP1 and TSG101. 
 
 
 
 
 
A. Ibrahim and E. Marban, Annual Review of Physical Chemistry; 2016 
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Fig. 3 
Image representing the four ESCRT complexes. ESCRT 0 complex proteins (B 
represents a ubiquitin group bound to a protein substrate) recognize ubiquitinated 
protein and recruit ESCRT I, which in turn recruits ESCRT II and triggers 
membrane involution. ESCRT III complexes cause further invagination of the 
membrane and ultimately both membrane abscission and budding of the proteins 
into the lumen of the endosome and the elimination of ubiquitin outside the 
endosome. 
 
 
 
A. Ibrahim and E. Marban, Annual Review of Physical Chemistry; 2016 
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Tab. 1 
List of primer sequences used for Real-time PCR analysis. 
45 
 
 
 
 
 
 
 
 
  
Fig. 4  
Phase contrast microscope images of primary cell cultures obtained from 
normal (A) and pathological (B) adult human hearts.  
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Fig. 5 
Phase contrast microscope image of CF-P in culture. 
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Fig. 6 
Immunomagnetic cell sorting: preventive cardiac fibroblasts depletion from 
primary culture (A) and CD117(+) cardiac primitive cells isolation (B-C). 
Fluorescence microscope images of CD117(+) cardiac primitive cells (D). 
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Fig. 7 
Phase contrast microscope images of CPC-N (A) and CPC-P (B) in 
culture.  
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Fig. 8 
Agarose (2.5%) gel electrophoresis of PCR products. (A) Cardiac 
differentiation transcripts; (B) Mesenchymal differentiation transcripts. 
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Fig. 9 
Expression levels of mRNAs from Exo-CPC-N and Exo-CPC-P. 
Statistically significant differences, indicated by * (p<0.05), only 
emerged for MEF2C, Nkx2.5, SMA and TM4SF1. 
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Fig. 10 
Growth Factor array analysis of Exo-CPC-N and Exo-CPC-P cargo. Table of 
searched Growth Factors (A); membranes with spots representing Growth Factors 
carried by Exo-CPC-N (B) and Exo-CPC-P (C). 
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Fig. 11 
Microscopic images of vital stainings of CPC-P in culture, either in 
the absence (A, C) or presence (B, D) of Exo-CPC-N. Phase contrast 
images of CPC-P (A, B); cells in G1-S-G2-M phase of cell cycle (C, 
D). Proliferative (E) rates of CPC-P treated with Exo-CPC-N and 
CPC-P untreated (control group). Statistically significant results are 
indicated by * (p<0.05). 
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Fig. 12 
Phase contrast microscope images of CPC-P in absence (A) or 
presence (B) of Exo-CPC-N. Images of apoptotic cells after Cell-
ApoPercentage Apoptosis assay (C, D). Apoptotic rates (E) of CPC-P 
treated with Exo-CPC-N and CPC-P untreated (control group). 
Statistically significant results are indicated by * (p<0.05). 
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Fig. 13 
Microscopic images of migration of CPC-P, either in the absence (A, C) 
or presence (B, D) of Exo-CPC-N. T0 (A, B) and after 8 hours (C, D). 
Speed of migration of CPC-P untreated and treated with Exo-CPC-N 
(E). No statistically significant differences were observed. 
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Fig. 14 
Phase contrast microscope images of CF-P in culture, 
either in the absence (A) or presence (E) of Exo-CPC-N. 
Fluorescence microscope images of CF-P in culture, 
either in the absence (B, C, D) or presence (F, G, H) of 
Exo-CPC-N. Collagen IV and Nuclei of cells (B, F); 
Laminin and Nuclei of cells (C, G); Fibronectin and 
Nuclei of cells (D, H). 
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PROTEIN CF-P TREATED CF-P UNTREATED  
 
Collagen IV ++ + 
Laminin + ++ 
Fibronectin +++ ++ 
Tab. 2  
Framework of results observed for synthesis and 
deposition of collagen IV, laminin and fibronectin 
quantified using an arbitrary scale ranging from negative 
(-) in case of immunonegativity, to triple positive (+++) 
in case of strong immunopositivity. 
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